Related Experiment Video

Updated: Jun 11, 2025

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

6.8K

β-arrestin2: an emerging player and potential therapeutic target in inflammatory immune diseases

Ping-Ping Gao1, Ling Li1, Ting-Ting Chen1

  • 1Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Hefei, 230032, China.

Acta Pharmacologica Sinica
|September 30, 2024
PubMed

Insights

Beta-arrestin2 is crucial in immune responses and inflammatory diseases. Targeting beta-arrestin2 presents a promising therapeutic strategy for treating various immune-related inflammatory conditions.

Area of Science:

  • Molecular Biology
  • Immunology
  • Cell Biology

Background:

  • Beta-arrestin2 (β-arrestin2) is a key protein regulating G protein-coupled receptors (GPCRs) signaling.
  • It functions in the cytoplasm, plasma membrane, and nucleus, influencing cellular processes.
  • Emerging evidence highlights its non-GPCR roles in various signaling pathways.

Purpose of the Study:

  • To review the multifaceted roles of β-arrestin2 in inflammatory immune responses.
  • To explore the pathological significance of β-arrestin2 in diverse inflammatory immune diseases.
  • To assess the therapeutic potential of modulating β-arrestin2 for disease treatment.

Main Methods:

  • Literature review of studies on β-arrestin2 function and involvement in disease.
  • Analysis of β-arrestin2's dual role in GPCR desensitization and scaffolding.
  • Examination of β-arrestin2's impact on non-GPCR pathways (NF-κB, MAPK, TGF-β).

Main Results:

  • β-arrestin2 mediates GPCR desensitization and internalization.
  • It acts as a scaffold for kinase activation and signaling pathway modulation.
  • β-arrestin2 is essential for immune cell infiltration, inflammatory factor release, and proliferation.

Conclusions:

  • β-arrestin2 is integral to the pathogenesis of inflammatory immune diseases.
  • Its involvement spans conditions like inflammatory bowel disease, sepsis, asthma, rheumatoid arthritis, fibrosis, and tumors.
  • Targeting β-arrestin2 represents a promising therapeutic avenue for inflammatory immune diseases.
Keywords:
cell signalingdrug targetimmune cellsinflammatory immune diseasesinflammatory immune responseβ-arrestin2

More Related Videos

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin13:45

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Published on: December 23, 2010

12.8K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

43

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
597
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
118
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.9K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143